Jounce, ObsEva file for IPOs

Cancer immunotherapy company Jounce Therapeutics Inc. (Cambridge, Mass.) and reproductive health play ObsEva S.A. (Geneva, Switzerland) each filed for IPOs on NASDAQ on Friday.

Jounce proposed to raise up to $75 million in an offering underwritten by JPMorgan, Cowen, Wells Fargo and Baird. The company expects data in 1H17 from a Phase I/II study of lead candidate JTX-2011 in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid tumors. JTX-2011 is an inducible T cell co-stimulator (ICOS) agonist antibody. ...